张文宏

发布时间：2021-06-28浏览次数：15530

教师基本信息

姓名：张文宏

职称：教授

电子邮箱：zhangwenhong@fudan.edu.cn

办公地点：生科院C507

个人简介

张文宏，男，教授，博士生导师，mg4355娱乐线路检测官网PI。教育部长江学者特聘教授，国家卫健委突出贡献中青年专家，全国抗击新冠肺炎疫情先进个人，全国优秀共产党员。现任国家传染病医学中心主任，mg4355电子娱乐官网附属华山医院感染科主任，mg4355电子娱乐官网临床医学院内科学系主任，上海市传染病与生物安全应急响应重点实验室主任，上海市新冠肺炎医疗救治专家组组长。

获奖情况

荣获全国创新争先奖、上海市科技进步一等奖、上海市科普奖特等奖、中华医学会医学奖、上海市医学科技奖等多项科技成果奖；并先后获得全国科普工作先进工作者、国家健康科普专家库入选者、上海市市长质量奖、2020年“最美教师、2021年“中国城市人物”、首届“国之名医·优秀风范”奖、科普杰出人物奖等奖。

研究成果及贡献

长期专注于重大传染性疾病流行消除诊治创新技术的探索，并对新发突发传染病的预警与大流行应对技术的建立作出贡献。主要包括以下几个方面：

（一）消除结核病流行关键技术研究。长期致力于中国结核病流行消除与耐多药结核病诊治新技术方案探索。注册中国最早的潜伏结核短程预防方案的RCT研究，优化和首创超短程潜伏结核预防治疗，将疗程从3个月缩短至1个月，在中国西部广泛用于消除校园结核病的临床实践；提出国际上创新的短程治疗策略，突破我国耐多药结核病不足50%的低治愈率瓶颈；牵头全国多中心临床研究（中国PZA研究），研发出治愈率超80%的12个月短程治疗方案，被《耐多药结核病短程治疗中国专家共识》、《中国耐多药和利福平耐药结核病治疗专家共识(2019年版)》、《耐药结核病诊治规范(2019年版)》三个共识/规范共同推荐。耐多药结核病治疗方案连续被2016、2018、2022年WHO耐多药结核病指南引用。

（二）致力于慢性乙肝的功能性治愈新策略研究。团队长期致力于肝病的功能性治愈，明确了血清HBV-RNA水平与功能性治愈相关核心分子cccDNA的肝内转录活性的相关性。开发了针对慢性乙型肝炎的非整合型慢病毒载体治疗性疫苗，大型临床研究验证了分阶段免疫叠加治疗获得更高功能性治愈的治疗理念。（三）新发传染病的鉴定、监测与大流行准备技术研究。2013年起建立全国首个感染性疾病病原精准诊断中心平台，在全球首次经病原学和免疫学角度分别验证猪伪狂犬病毒跨物种传播，完成国际第一例通过宏基因组学技术快速鉴定非洲锥虫病并成功救治危重患者的案例；在我国北方建立大型布鲁菌病队列，自然史研究成为国际医学教育项目（ACCME）的经典案例；2020年新冠疫情爆发以来，在全球首次对两针灭活疫苗+重组蛋白疫苗序贯免疫的保护性及其机制进行了研究，为国家第三针加强策略的部署提供依据；2023年全国首次报道奥密克戎长新冠队列随访结果。团队上述多个成果或被WHO指导文件引用并发表于高质量国际论文上。以第一作者/通讯作者在国内外期刊上发表论文300余篇，包括SCI论文200余篇。研究成果获国家授权专利9项，主编及参编各类感染病学专著20余部。

科研项目（近3年）

落地生科院包括国家重大专项、上海市重大专项、校企联合实验室等纵向和联合实验室横向科研项目，总经费超3000万元.

招生专业

微生物学、遗传学

部分代表性论文（近3年）

  1. Zhang, Y., Q. Jiang, F. Sun, J. Wang, J. Wu, H. Yao, S. Li, N. Jiang, Q. Liu, Q. Liu, Y. Zhang, Y. Zhao, C. Chen, P. Cui, J. Jin and W. Zhang (2023). "Genomic tracking and precise control of Klebsiella pneumoniae transmission in a newly established hospital: a prospective molecular epidemiological study." Int J Antimicrob Agents 62(3): 106910.

  2. Zhang, H., M. Zhang, Q. Zhang, Y. Yu, F. Zhang, J. Wang, M. Zhou, T. Yu, C. Shen, S. Yu, Y. Huang, Y. Huang, J. Zhang, J. Jin, C. Qiu, L. Guojun and W. Zhang (2023). "Visualizing in situ viral replication across the natural history of chronic HBV infection." Hepatol Commun 7(4).

  3. Wu, Z., L. Lu, Y. Li, J. Chen, Z. Zhang, C. Ning, Z. Yuan, Q. Pan, X. Shen and W. Zhang (2023). "Effect of mobile health reminders on tuberculosis treatment outcomes in Shanghai, China: A prospective cohort study." Front Public Health 11: 923319.

  4. Wu, Q., H. Wang, J. Cai, J. Ai, Y. Li, H. Zhang, S. Wang, F. Sun, Y. Wu, J. Zhou, Y. Wang, H. Yu and W. Zhang (2023). "Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai." Emerg Microbes Infect 12(1): e2169197.

  5. Wang, H., Q. Xue, H. Zhang, G. Yuan, X. Wang, K. Sheng, C. Li, J. Cai, Y. Sun, J. Zhao, J. Lu, S. Fang, Y. Yang, Y. Zhang, Y. Huang, J. Wang, J. H. Xu, M. X. Jiang, X. Wang, L. Shen, Y. Liu, Q. Liu, Q. Zhang, S. Wang, P. Wang, C. Qiu, J. Ai and W. Zhang (2023). "Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination(1)." Emerg Microbes Infect 12(2): 2249121.

  6. Song, J., K. Zhu, X. Wang, Q. Yang, S. Yu, Y. Zhang, Z. Fu, H. Wang, Y. Zhao, K. Lin, G. Yuan, J. Guo, Y. Shi, C. Liu, J. Ai, H. Zhang and W. Zhang (2023). "Utility of clinical metagenomics in diagnosing malignancies in a cohort of patients with Epstein-Barr virus positivity." Front Cell Infect Microbiol 13: 1211732.

  7. Ruan, Q. L., Z. C. Wang, C. J. Wei, W. Wang, Q. L. Yang, J. Wu, Y. M. Wan, L. L. Ge, W. H. Zhang and Q. F. Li (2023). "Neutralizing antibodies against SARS-CoV-2 virus after vaccination in patients with neurofibromatosis type 1." Signal Transduct Target Ther 8(1): 233.

  8. Li, R., Y. Li, X. Chen, L. Jia, H. Yu, Y. Huang, Q. Wu, M. Xiao, S. Ge, Y. Zhang, Z. Feng, Q. Li, Y. Xu, W. Shi, F. Sun and W. Zhang (2023). "Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients." Microbiol Spectr 11(3): e0483622.

  9. Fu, Z., J. Ai, H. Zhang, P. Cui, T. Xu, Y. Zhang, Y. Zhang, H. Wu, A. Shen, K. Lin, M. Zhang, C. Qiu, N. Jiang, Y. Zhou and W. Zhang (2023). "Pathogen quantitative efficacy of different spike-in internal controls and clinical application in central nervous system infection with metagenomic sequencing." Microbiol Spectr: e0113923.

  10. Fu, L., X. Zhang, J. Xiong, F. Sun, T. Weng, Y. Li, P. Zhang, H. Li, Q. Yang, Y. Cai, H. Liang, Q. Chen, Z. Wang, L. Liu, X. Chen, W. Zhang and G. Deng (2023). "Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study." Int J Infect Dis 135: 101-108.

  11. Chen, X., R. Li, S. Ge, Y. Li, C. Cai, T. Weng, Y. Zhang, J. Jiang, Z. Feng, Y. Chen, Y. Zhang, J. Ma, D. H. Persing, J. Chen, Y. W. Tang, F. Sun and W. Zhang (2023). "Rapid Detection of Extensive Drug Resistance by Xpert MTB/XDR Optimizes Therapeutic Decision-Making in Rifampin-Resistant Tuberculosis Patients." J Clin Microbiol 61(6): e0183222.

  12. Cai, J., K. Lin, H. Zhang, Q. Xue, K. Zhu, G. Yuan, Y. Sun, F. Zhu, J. Ai, S. Wang and W. Zhang (2023). "A one-year follow-up study of systematic impact of long COVID symptoms among patients post SARS-CoV-2 omicron variants infection in Shanghai, China." Emerg Microbes Infect 12(2): 2220578.

  13. Zhang, Y., H. Zhang and W. Zhang (2022). "SARS-CoV-2 variants, immune escape, and countermeasures." Front Med 16(2): 196-207.

  14. Zhang, Y., N. Jiang, W. Qi, T. Li, Y. Zhang, H. Zhang, J. Wu, Z. Zhu, J. Ai, C. Qiu and W. Zhang (2022). "Intra-host SARS-CoV-2 single-nucleotide variants emerged during the early stage of COVID-19 pandemic forecast population fixing mutations." J Infect 84(5): 722-746.

  15. Zhang, Y., N. Jiang, W. Qi, T. Li, Y. Zhang, J. Wu, H. Zhang, M. Zhou, P. Cui, T. Yu, Z. Fu, Y. Zhou, K. Lin, H. Wang, T. Wei, Z. Zhu, J. Ai, C. Qiu and W. Zhang (2022). "SARS-CoV-2 intra-host single-nucleotide variants associated with disease severity." Virus Evol 8(2): veac106.

  16. Zhang, Y., J. Ai, J. Bao and W. Zhang (2022). "Lessons learned from the COVID-19 control strategy of the XXXII Tokyo Summer Olympics and the XXIV Beijing Winter Olympics." Emerg Microbes Infect 11(1): 1711-1716.

  17. Zhang, X., W. Zhang and S. Chen (2022). "Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic." Lancet 399(10340): 2011-2012.

  18. Zhang, H., W. Hua, S. Lin, Y. Zhang, X. Chen, S. Wang, J. Chen and W. Zhang (2022). "In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid." Infect Drug Resist 15: 4845-4852.

  19. Yang, Q. L., S. L. Yu, L. Y. Shao, Q. L. Ruan and W. H. Zhang (2022). "A 70-Year-Old Man With Fever and Fatigue." Clin Infect Dis 74(6): 1117-1119.

  20. Wang, X., J. Ai, X. Li, X. Zhao, J. Wu, H. Zhang, X. He, C. Zhao, R. Qiao, M. Li, Y. Cui, Z. Hu, C. Xu, W. Zhang and P. Wang (2022). "Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera." Cell Discov 8(1): 110.

  21. Wang, H., W. Zhang and Y. W. Tang (2022). "Clinical microbiology in detection and identification of emerging microbial pathogens: past, present and future." Emerg Microbes Infect 11(1): 2579-2589.

  22. Ruan, Q. L., Q. L. Yang, F. Sun, W. Liu, Y. J. Shen, J. Wu, N. Jiang, J. Y. Zhou, L. Y. Shao and W. H. Zhang (2022). "Recurrent pulmonary tuberculosis after treatment success: a population-based retrospective study in China." Clin Microbiol Infect 28(5): 684-689.

  23. Qi, X., J. Wang, Q. Zhang, J. Ai, C. Liu, Q. Li, Y. Gu, J. Lv, Y. Huang, Y. Liu, D. Xu, S. Chen, D. Liu, J. Li, H. Xiang, J. Liang, L. Bian, Z. Zhang, L. Liu, X. Zhang, W. Qin, X. Wang, Z. Hou, N. Zhang, A. Zhang, H. Zu, Y. Wang, Z. Yan, X. Du, A. Hou, J. Ji, J. Yang, J. Huang, Z. Zhao, S. Zou, H. Ji, G. Ge, Q. L. Zeng and W. Zhang (2022). "Safety and immunogenicity of COVID-19 vaccination in patients with hepatocellular carcinoma (CHESS-NMCID 2101): A multicenter prospective study." J Med Virol 94(11): 5553-5559.

  24. Ma, E., J. Ai, Y. Zhang, J. Zheng, X. Gao, J. Xu, H. Yin, Z. Fu, H. Xing, L. Li, L. Sun, H. Huang, Q. Zhang, L. Xu, Y. Jin, R. Chen, G. Lv, Z. Zhu, W. Zhang and Z. Wang (2022). "Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort." Emerg Microbes Infect 11(1): 2636-2644.

  25. Jia, L., S. Weng, J. Wu, X. Tian, Y. Zhang, X. Wang, J. Wang, D. Yan, W. Wang, F. Fang, Z. Zhu, C. Qiu, W. Zhang, Y. Xu and Y. Wan (2022). "Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity." Gut Microbes 14(1): 2117503.

  26. Chen, X., H. Wang, J. Ai, L. Shen, K. Lin, G. Yuan, X. Sheng, X. Jin, Z. Deng, J. Xu, G. Lu, S. Chen, J. Cai, Y. Zhang, H. Zhang, S. Wang, W. Zhang and C. Fan (2022). "Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multi-centre cohort study." Emerg Microbes Infect 11(1): 2501-2509.

  27. Bao, J., R. Sun, J. Ai, L. Qian, F. Liu, H. Wang, L. Tan, X. Cai, Y. Shi, X. Liang, W. Ge, J. Wu, C. Chen, W. Zhang, J. Huang and T. Guo (2022). "Proteomic characterization of Omicron SARS-CoV-2 host response." Cell Discov 8(1): 46.

  28. Ai, J., Y. Zhang, H. Zhang, Q. Zhang, Z. Fu, K. Lin, J. Song, Y. Zhao, M. Fan, H. Wang, Y. Zhou, X. Chen, C. Qiu and W. Zhang (2022). "Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study." Emerg Microbes Infect 11(1): 639-647.

  29. Ai, J., H. Zhang, Y. Zhang, K. Lin, Y. Zhang, J. Wu, Y. Wan, Y. Huang, J. Song, Z. Fu, H. Wang, J. Guo, N. Jiang, M. Fan, Y. Zhou, Y. Zhao, Q. Zhang, Q. Liu, J. Lv, P. Li, C. Qiu and W. Zhang (2022). "Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost." Emerg Microbes Infect 11(1): 337-343.

  30. Ai, J., H. Zhang, Q. Zhang, Y. Zhang, K. Lin, Z. Fu, J. Song, Y. Zhao, M. Fan, H. Wang, C. Qiu, Y. Zhou and W. Zhang (2022). "Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern." Cell Res 32(1): 103-106.

  31. Ai, J., X. Wang, X. He, X. Zhao, Y. Zhang, Y. Jiang, M. Li, Y. Cui, Y. Chen, R. Qiao, L. Li, L. Yang, Y. Li, Z. Hu, W. Zhang and P. Wang (2022). "Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages." Cell Host Microbe 30(8): 1077-1083.e1074.

  32. Ai, J., J. Guo, H. Zhang, Y. Zhang, H. Yang, K. Lin, J. Song, Z. Fu, M. Fan, Q. Zhang, H. Wang, Y. Zhao, Z. He, A. Cui, Y. Zhou, J. Wu, M. Zhou, G. Yuan, B. Kang, N. Zhao, Y. Xu, M. Zhu, Y. Wang, Z. Zhang, N. Jiang, C. Qiu, C. Xu and W. Zhang (2022). "Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or heterologous booster vaccination analyzed by single-cell immune profiling." Cell Discov 8(1): 114.